Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Average Rating of "Buy" by Brokerages

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) has been assigned an average rating of "Buy" from the five brokerages that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $9.33.

Separately, HC Wainwright restated a "buy" rating and issued a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Trading Down 2.0%

Shares of CRBU stock opened at $0.77 on Monday. The company has a market cap of $72.01 million, a price-to-earnings ratio of -0.47 and a beta of 2.36. The stock has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.45. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.92.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.01). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, equities analysts forecast that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Sei Investments Co. acquired a new stake in shares of Caribou Biosciences in the 4th quarter worth approximately $102,000. JPMorgan Chase & Co. grew its holdings in Caribou Biosciences by 475.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after buying an additional 2,062,563 shares during the last quarter. US Bancorp DE grew its holdings in Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock valued at $43,000 after buying an additional 26,467 shares during the last quarter. American Century Companies Inc. grew its holdings in Caribou Biosciences by 9.2% during the 4th quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock valued at $254,000 after buying an additional 13,421 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in Caribou Biosciences by 74.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company's stock valued at $297,000 after buying an additional 79,636 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.